 WOBURN, Mass., Aug. 02, 2021 GLOBE NEWSWIRE -- Replimune Group, Inc. NASDAQ: REPL, a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences: 